GO:0036297 interstrand cross-link repair: DNA Damage Response Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0036297 (interstrand cross-link repair) describes the removal of covalent links between opposite DNA strands and restoration of the duplex, a process essential for transcription and replication.
• Interstrand cross-links (ICLs) block strand separation and are repaired through coordinated incision, unhooking, translesion synthesis, and homologous recombination steps.
• The Fanconi anemia (FA) pathway is the central coordinator of ICL repair in vertebrates, with over 20 FA genes identified.
• Defects in ICL repair cause Fanconi anemia, a genome instability syndrome with bone marrow failure, developmental abnormalities, and cancer predisposition.
• ICL repair is cell-cycle regulated, with distinct mechanisms operating in G1 (polymerase zeta-dependent) and S/G2 phases (replication-coupled).
• Research tools include CRISPR knockout models, ICL-inducing agents (mitomycin C, cisplatin), and specialized assays for repair intermediates.
Description
Interstrand cross-link repair (GO:0036297) is the biological process that removes covalent attachments between DNA bases on opposite strands of the double helix and restores the DNA to its functional state. These cross-links, whether induced by exogenous agents such as cisplatin or mitomycin C, or formed endogenously by reactive metabolites, prevent the strand unwinding required for transcription and replication, making their repair essential for cell survival. The importance of this process is underscored by the fact that defects in ICL repair cause Fanconi anemia, a devastating inherited disorder characterized by bone marrow failure, congenital abnormalities, and heightened cancer susceptibility. Understanding the molecular mechanisms of ICL repair has therefore become a major focus in genome stability research, with implications for cancer therapy, drug development, and our fundamental knowledge of DNA damage responses. This article synthesizes current knowledge on the genes, mechanisms, and research methods used to study interstrand cross-link repair, providing a comprehensive resource for researchers investigating this critical DNA repair pathway.
interstrand cross-link repair At A Glance
| GO ID | GO:0036297 |
|---|---|
| GO term | interstrand cross-link repair |
| Ontology | biological_process |
| Synonym | ICL repair |
| Major function | Removal of covalent cross-links between DNA strands and restoration of DNA integrity |
| Cellular context | Nucleus; active during S phase and G1 phase with distinct mechanisms |
| Key pathway | Fanconi anemia (FA) pathway coordinates ICL repair in vertebrates |
| Associated diseases | Fanconi anemia, cancer predisposition, bone marrow failure |
| Research relevance | Target for cancer therapy, understanding chemoresistance, genome stability |
What Is GO:0036297?
Interstrand cross-link repair is the cellular process that removes covalent bonds linking the two complementary strands of DNA and restores the double helix to its normal structure. Interstrand cross-links (ICLs) occur when DNA bases on opposite strands become covalently tethered together, typically by bifunctional alkylating agents or endogenous reactive molecules. Because these cross-links physically prevent the separation of DNA strands, they block essential processes such as transcription and replication, leading to cell cycle arrest and cell death if left unrepaired. The repair process involves multiple coordinated steps including damage recognition, incision on either side of the cross-link, unhooking of the lesion, translesion DNA synthesis past the damaged site, and homologous recombination-mediated repair of the resulting double-strand break.
Why Is interstrand cross-link repair Important in Cell Biology?
Interstrand cross-link repair is critically important because ICLs are among the most toxic DNA lesions, blocking both transcription and replication by preventing strand separation. Cells deficient in ICL repair accumulate DNA damage, leading to genomic instability, cell cycle arrest, and apoptosis. The clinical significance of this pathway is exemplified by Fanconi anemia, where mutations in ICL repair genes cause bone marrow failure, developmental defects, and a markedly increased risk of leukemia and other cancers. Furthermore, many chemotherapeutic agents, including cisplatin and mitomycin C, exert their cytotoxic effects by inducing ICLs, making ICL repair a key determinant of drug sensitivity and resistance in cancer treatment. Understanding this pathway also provides insights into normal developmental processes, as ICL repair genes are essential for maintaining genome integrity in stem cells and proliferating tissues.
• ICLs are among the most cytotoxic DNA lesions, blocking replication and transcription by preventing strand separation.
• Defective ICL repair causes Fanconi anemia, a disorder characterized by bone marrow failure and cancer predisposition.
• The FA pathway coordinates ICL repair and involves over 20 genes mutated in Fanconi anemia patients.
• ICL repair is cell-cycle regulated, with polymerase zeta playing a critical role in G1 phase.
• Many anticancer drugs (cisplatin, mitomycin C) work by inducing ICLs, making repair a determinant of chemosensitivity.
• ICL repair defects are associated with increased susceptibility to serrated polyposis syndrome.
• Understanding ICL repair informs development of targeted cancer therapies and chemosensitizers.
• ICL repair mechanisms are conserved from yeast to humans, enabling model organism studies.
• Research tools include CRISPR screens, repair intermediate assays, and ICL-inducing agents.
• ICL repair intersects with other DNA repair pathways including homologous recombination and translesion synthesis.
What Happens During interstrand cross-link repair?
Damage recognition and Fanconi anemia pathway activation
In simple terms: The cell first detects the cross-link and sounds an alarm that recruits repair proteins.
The repair process begins when the cell recognizes an interstrand cross-link, often during replication fork stalling. The Fanconi anemia (FA) core complex, consisting of multiple proteins including FANCA, FANCB, FANCC, and others, is activated and monoubiquitinates the FANCD2-FANCI heterodimer. This ubiquitination is a key regulatory step that targets FANCD2-FANCI to chromatin at the site of the cross-link, serving as a platform for recruiting downstream repair factors including nucleases and homologous recombination proteins. The recognition step is critical because it determines whether the cell will attempt repair or undergo apoptosis.
Incision and unhooking of the cross-link
In simple terms: Enzymes cut the DNA around the cross-link to unhook it from one strand.
Following activation, structure-specific nucleases including XPF-ERCC1, SLX4, and FAN1 are recruited to make incisions on one strand flanking the cross-link. This incision process unhooks the cross-link, leaving the lesion attached to the opposite strand while creating a double-strand break intermediate. The coordination of incisions is tightly regulated to prevent excessive DNA damage, with multiple nucleases acting redundantly or sequentially depending on the context. The unhooking step is essential because it converts the covalent cross-link into a lesion that can be bypassed by translesion synthesis.
Translesion synthesis past the unhooked cross-link
In simple terms: Specialized polymerases copy DNA past the remaining damaged base.
After unhooking, the remaining cross-linked base on the opposite strand must be bypassed to allow repair to continue. Translesion synthesis (TLS) polymerases, particularly polymerase zeta (REV3L/REV7), are recruited to replicate past the lesion. In G1 phase, polymerase zeta plays a critical role in ICL repair, allowing the cell to complete repair outside of S phase. Other TLS polymerases including REV1 and polymerase kappa may also contribute to bypass in different contexts. This step is error-prone and can introduce mutations, but it is essential for restoring a functional DNA duplex.
Homologous recombination and restoration of the DNA duplex
In simple terms: The broken DNA is repaired using the intact sister chromatid as a template.
The incision and unhooking steps generate a double-strand break that must be repaired by homologous recombination (HR) to restore the DNA duplex accurately. Key HR proteins including RAD51, BRCA1, BRCA2, and the MRN complex are recruited to the damage site. The sister chromatid, if available during S/G2 phase, serves as a template for error-free repair. In G1 phase, when no sister chromatid is present, alternative mechanisms involving polymerase zeta and other factors allow repair to proceed, albeit with different fidelity. The final steps involve resolution of recombination intermediates and ligation to restore intact DNA.
Cell cycle regulation of ICL repair
In simple terms: The repair strategy changes depending on where the cell is in its division cycle.
ICL repair is differentially regulated across the cell cycle, with distinct mechanisms operating in G1 versus S/G2 phases. In S phase, replication-coupled ICL repair is the primary mechanism, using the sister chromatid for homologous recombination-based repair. In G1 phase, when no sister chromatid is available, repair relies heavily on polymerase zeta-mediated translesion synthesis and other error-prone mechanisms. This cell cycle dependence ensures that repair is coordinated with DNA replication and that the appropriate repair pathway is used based on the availability of templates. Understanding this regulation is critical for interpreting experimental results and for developing therapeutic strategies that target ICL repair.
Key Genes Involved in GO:0036297 interstrand cross-link repair
The following genes encode proteins with established roles in interstrand cross-link repair, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FANCA | Core complex component; essential for FANCD2 monoubiquitination | Most commonly mutated in Fanconi anemia; knockout models show ICL sensitivity |
| FANCD2 | Monoubiquitinated platform for repair factor recruitment | Key marker of FA pathway activation; knockout causes ICL repair defect |
| FANCI | Partner of FANCD2; required for monoubiquitination | Mutations cause Fanconi anemia; important for damage recognition |
| FANCC | Core complex component; involved in FANCD2 activation | Fanconi anemia subtype; knockout cells sensitive to mitomycin C |
| FANCE | Core complex component; required for FANCD2 monoubiquitination | Fanconi anemia gene; knockout models available |
| FANCF | Core complex component; stabilizes FA core complex | Fanconi anemia gene; commonly used in research models |
| FANCG | Core complex component; interacts with FANCA | Fanconi anemia gene; knockout shows ICL sensitivity |
| FANCL | E3 ubiquitin ligase for FANCD2 monoubiquitination | Essential for FA pathway; knockout abolishes FANCD2 ubiquitination |
| FANCM | DNA translocase; recognizes stalled replication forks | Fanconi anemia gene; involved in damage recognition |
| FANCP/SLX4 | Scaffold for nucleases; coordinates incisions | Fanconi anemia gene; critical for unhooking step |
| FANCQ/XPF-ERCC1 | Nuclease complex; makes incisions flanking ICL | Fanconi anemia gene; mutations cause repair defect |
| FAN1 | Nuclease; involved in unhooking and repair | Fanconi anemia-associated; important for incision regulation |
| BRCA1 | Homologous recombination; repair of double-strand breaks | Fanconi anemia gene; breast/ovarian cancer predisposition |
| BRCA2/FANCD1 | Homologous recombination; RAD51 loading | Fanconi anemia gene; breast/ovarian cancer predisposition |
| RAD51 | Homologous recombination; strand invasion | Key HR protein; essential for ICL repair in S/G2 |
| REV3L | Catalytic subunit of polymerase zeta; translesion synthesis | Critical for G1 phase ICL repair; knockout sensitive to ICLs |
| REV7/MAD2L2 | Regulatory subunit of polymerase zeta | Required for G1 phase ICL repair; knockout models available |
| ALKBH2 | Dioxygenase; repairs ethenoadenine lesions | Generates stable ICLs; relevant to endogenous damage |
How Is interstrand cross-link repair Regulated?
Interstrand cross-link repair is regulated at multiple levels, including cell cycle-dependent activation and post-translational modifications. The Fanconi anemia pathway is activated by replication stress and DNA damage, with FANCD2 monoubiquitination serving as a key regulatory event. In G1 phase, polymerase zeta is specifically required for ICL repair, while S/G2 phase repair relies on homologous recombination. The ATR kinase is a major upstream regulator that phosphorylates multiple FA proteins in response to replication fork stalling. Additionally, the ubiquitin-proteasome system regulates the stability and activity of repair factors, and deubiquitination enzymes such as USP1 counteract FANCD2 monoubiquitination to prevent excessive repair. This multilayered regulation ensures that ICL repair is tightly coordinated with cell cycle progression and DNA replication.
interstrand cross-link repair and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FANCA | Fanconi anemia, bone marrow failure, cancer predisposition | CRISPR knockout in hematopoietic stem cells; mitomycin C sensitivity assay |
| FANCD2 | Fanconi anemia, ICL repair defect | Knockout cell lines; FANCD2 monoubiquitination Western blot |
| BRCA2/FANCD1 | Fanconi anemia, breast/ovarian cancer | Knockout in breast epithelial cells; cisplatin sensitivity |
| FANCP/SLX4 | Fanconi anemia, ICL repair deficiency | Knockout cells; chromosomal breakage assay |
| ALKBH2 | Endogenous ICL formation, metabolic stress | Overexpression and knockout models; ethenoadenine repair assays |
Fanconi anemia and bone marrow failure
Fanconi anemia is the prototypical disease caused by defective interstrand cross-link repair, resulting from biallelic mutations in any of over 20 FA genes. Patients present with progressive bone marrow failure, congenital abnormalities including skeletal defects and skin pigmentation changes, and a markedly increased risk of acute myeloid leukemia and squamous cell carcinomas. The bone marrow failure is thought to result from the accumulation of DNA damage in hematopoietic stem cells, leading to stem cell exhaustion. Diagnosis is confirmed by increased chromosomal breakage in lymphocytes exposed to ICL-inducing agents such as mitomycin C or diepoxybutane. Understanding the molecular basis of Fanconi anemia has provided critical insights into ICL repair mechanisms and has guided the development of targeted therapies.
Cancer predisposition and chemosensitivity
Defects in ICL repair genes are associated with increased cancer susceptibility beyond Fanconi anemia, including breast and ovarian cancers (BRCA1, BRCA2/FANCD1, PALB2/FANCN) and serrated polyposis syndrome. Germline variants in ICL repair genes may contribute to increased susceptibility for serrated polyposis syndrome, a condition characterized by multiple serrated polyps in the colon and increased colorectal cancer risk. Conversely, cancer cells with defective ICL repair are hypersensitive to cross-linking agents such as cisplatin and mitomycin C, which is exploited therapeutically. However, acquired resistance to these drugs often involves restoration of ICL repair capacity, making this pathway a target for therapeutic intervention. Understanding the relationship between ICL repair defects and cancer has led to the development of PARP inhibitors and other targeted therapies.
Endogenous sources of interstrand cross-links and metabolic stress
Beyond exogenous agents, endogenous metabolic processes can generate interstrand cross-links, contributing to the pathology of various diseases. For example, the repair of 1,N(6)-ethenoadenine by ALKBH2 can generate stable interstrand cross-links, linking ICL repair to cellular metabolism and oxidative stress. These endogenous lesions may contribute to aging and degenerative diseases, particularly in tissues with high metabolic activity. Understanding how endogenous ICLs are formed and repaired is an emerging area of research with implications for age-related diseases and metabolic disorders.
From interstrand cross-link repair-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X knockout cause ICL repair defect? | CRISPR knockout cell lines; mitomycin C sensitivity assay |
| Does mutation X affect FANCD2 monoubiquitination? | Point mutation knock-in; Western blot for ubiquitinated FANCD2 |
| Does gene X interact with FA pathway components? | Tagged knock-in (e.g., GFP, HA); co-immunoprecipitation |
| Does overexpression of gene X rescue ICL repair? | Overexpression cell lines; chromosomal breakage assay |
| What is the cell cycle phase requirement for gene X? | Knockout with cell cycle synchronization; ICL repair assays |
| Can gene X be targeted for cancer therapy? | CRISPR knockout in cancer cells; drug sensitivity screens |
How to Study the interstrand cross-link repair Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mitomycin C sensitivity assay | Cell survival after ICL induction | Characterizing knockout or mutant cell lines |
| Chromosomal breakage assay | Chromosome aberrations after ICL induction | Diagnosis of Fanconi anemia; validation of repair defects |
| FANCD2 monoubiquitination Western blot | Activation of FA pathway | Assessing pathway function in knockout/mutant cells |
| Repair intermediate analysis | Incision and unhooking of cross-links | Mechanistic studies of ICL repair steps |
| CRISPR knockout screens | Genes required for survival after ICL induction | Discovery of novel ICL repair genes |
| Immunofluorescence | Localization of repair proteins to damage sites | Studying recruitment and assembly of repair complexes |
| Yeast genetics | Epistasis and pathway relationships | Defining conserved repair mechanisms |
| Proteomics | Protein interactions and modifications | Identifying novel ICL repair factors and regulators |
ICL induction and cellular sensitivity assays
The most common approach to study ICL repair is to treat cells with cross-linking agents such as mitomycin C, cisplatin, or diepoxybutane, and measure cell survival or chromosomal breakage. Chromosomal breakage assays in lymphocytes are the diagnostic standard for Fanconi anemia, where cells from patients show increased chromosome aberrations upon ICL induction. Cell survival assays using clonogenic or MTT-based methods quantify sensitivity to ICL-inducing agents, with repair-deficient cells showing increased sensitivity. These assays are essential for characterizing the functional impact of gene knockouts or mutations in ICL repair genes.
Analysis of repair intermediates and FANCD2 monoubiquitination
Detailed mechanistic studies require analysis of repair intermediates, including the detection of incised DNA and unhooked cross-links. Methods have been developed to prepare DNA interstrand cross-link repair intermediates induced by abasic sites, allowing precise mapping of incision sites. FANCD2 monoubiquitination is a key marker of FA pathway activation and is typically assessed by Western blot, where a mobility shift indicates ubiquitination. Chromatin fractionation and immunofluorescence can determine whether FANCD2 and other repair proteins localize to damage sites. These techniques provide critical insights into the step-by-step progression of ICL repair.
CRISPR screens and functional genomics
CRISPR-based functional genomics screens have become powerful tools for identifying novel ICL repair genes and characterizing their roles. Genome-wide knockout screens using ICL-inducing agents can identify genes whose loss confers sensitivity or resistance, revealing new components of the repair pathway. These screens have confirmed known FA genes and identified additional factors involved in ICL repair, including nucleases, helicases, and recombination proteins. Combining CRISPR screens with transcriptomics or proteomics can provide a comprehensive view of the cellular response to ICLs. Such approaches are essential for understanding the full network of ICL repair and for identifying therapeutic targets.
Model organisms and yeast genetics
The yeast Saccharomyces cerevisiae has been instrumental in elucidating ICL repair mechanisms, with many genes conserved from yeast to humans. Yeast genetics allows rapid screening of gene deletions and epistasis analysis to define repair pathways. Key insights into incision, unhooking, and translesion synthesis have come from yeast studies, which are often more tractable than mammalian systems. However, vertebrates have additional complexity, including the expanded Fanconi anemia pathway, so findings must be validated in mammalian models. Combining yeast and mammalian studies provides a comprehensive understanding of ICL repair.
How CRISPR Can Be Used to Study GO:0036297 interstrand cross-link repair
Knockout
CRISPR knockout of ICL repair genes is a primary approach to study their function. For example, knocking out FANCA, FANCD2, or FANCL abolishes FANCD2 monoubiquitination and causes hypersensitivity to mitomycin C and cisplatin. Knockout cell lines are used to assess the contribution of specific genes to ICL repair, to map epistasis relationships, and to identify synthetic lethal interactions. Genome-wide knockout screens have identified numerous genes required for survival after ICL induction, expanding the known network of ICL repair factors. EDITGENE provides custom knockout cell models for any ICL repair gene, enabling researchers to dissect pathway mechanisms.
Point Mutation
Point mutation knock-in models allow precise interrogation of specific residues or domains within ICL repair proteins. For example, mutation of the FANCD2 ubiquitination site (K561) prevents monoubiquitination and impairs repair, mimicking a Fanconi anemia-like phenotype. Point mutations in nuclease domains of XPF or SLX4 can separate incision activity from scaffolding functions. These models are essential for understanding structure-function relationships and for validating patient-derived mutations. EDITGENE offers custom point mutation cell lines to study the functional consequences of specific variants in ICL repair genes.
Knock-in
Knock-in models, including tagged knock-ins (e.g., GFP, HA, or FLAG), enable visualization and biochemical analysis of ICL repair proteins. Tagged FANCD2 or FANCI knock-in cell lines allow real-time imaging of protein recruitment to damage sites and co-immunoprecipitation to identify interaction partners. Knock-in of patient-derived mutations can recreate disease-associated alleles in isogenic backgrounds, providing controlled systems to study genotype-phenotype relationships. These models are particularly valuable for studying the dynamic assembly of repair complexes at ICL sites. EDITGENE provides tagged knock-in and mutation knock-in services for ICL repair genes.
Overexpression
Overexpression of ICL repair genes can be used to test whether increased protein levels enhance repair capacity or rescue defects. For example, overexpression of FANCD2 or FANCI can partially rescue ICL repair in cells lacking upstream FA core complex components. Overexpression of nuclease-dead mutants can act as dominant-negative inhibitors, blocking repair and sensitizing cells to ICL-inducing agents. Overexpression models are also useful for producing large amounts of protein for structural studies or biochemical assays. EDITGENE offers overexpression cell lines for ICL repair genes to support functional and biochemical studies.
How EDITGENE Supports interstrand cross-link repair Research
Researchers studying interstrand cross-link repair-related genes often need to determine whether a candidate gene is causally involved in the pathway, how specific mutations affect protein function, and whether targeting the gene can sensitize cancer cells to cross-linking agents. EDITGENE provides a comprehensive suite of CRISPR-based cell model services to address these questions, from knockout and point mutation to knock-in and overexpression, along with library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for interstrand cross-link repair research.
Frequently Asked Questions About interstrand cross-link repair
What is interstrand cross-link repair?
Interstrand cross-link repair (GO:0036297) is the biological process that removes covalent bonds linking the two DNA strands and restores the double helix, allowing essential processes like transcription and replication to proceed.
What genes are involved in interstrand cross-link repair?
Key genes include the Fanconi anemia genes (FANCA, FANCB, FANCC, FANCD2, FANCI, FANCL, etc.), BRCA1, BRCA2/FANCD1, RAD51, REV3L, and nucleases such as XPF-ERCC1 and SLX4.
What diseases are associated with defective interstrand cross-link repair?
Defects cause Fanconi anemia, characterized by bone marrow failure, developmental abnormalities, and cancer predisposition. Germline variants are also linked to serrated polyposis syndrome and breast/ovarian cancers.
How is interstrand cross-link repair studied in the lab?
Common methods include treating cells with mitomycin C or cisplatin, measuring cell survival, chromosomal breakage assays, FANCD2 monoubiquitination Western blots, and CRISPR screens.
What is the role of the Fanconi anemia pathway in ICL repair?
The FA pathway coordinates ICL repair by activating FANCD2-FANCI monoubiquitination, recruiting nucleases for incision, and facilitating homologous recombination and translesion synthesis.
How does cell cycle stage affect interstrand cross-link repair?
In S/G2 phase, repair uses homologous recombination with the sister chromatid as a template. In G1 phase, polymerase zeta-mediated translesion synthesis is critical for repair.
What are the main steps of interstrand cross-link repair?
The main steps are damage recognition, FA pathway activation, incision and unhooking of the cross-link, translesion synthesis past the lesion, and homologous recombination to restore the DNA duplex.
Can CRISPR be used to study interstrand cross-link repair?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to study gene function, pathway mechanisms, and drug sensitivity in ICL repair.
What is the clinical significance of interstrand cross-link repair?
It determines sensitivity to cross-linking chemotherapies like cisplatin and mitomycin C, and defects cause Fanconi anemia and cancer predisposition, making it a target for therapeutic development.
What model organisms are used to study interstrand cross-link repair?
Saccharomyces cerevisiae is a key model due to conserved repair mechanisms, while mammalian cell lines and mouse models are used to study vertebrate-specific aspects including the FA pathway.
Conclusion
Interstrand cross-link repair (GO:0036297) is a critical DNA damage response pathway that protects genome integrity by removing covalent links between DNA strands. The Fanconi anemia pathway coordinates this repair through a series of well-orchestrated steps including damage recognition, incision, translesion synthesis, and homologous recombination. Defects in this pathway cause Fanconi anemia and increase cancer susceptibility, while also determining sensitivity to cross-linking chemotherapies. Continued research using CRISPR models, repair intermediate assays, and functional genomics will further elucidate the mechanisms of ICL repair and identify new therapeutic opportunities.
References
- 1. Semlow DR et al.. 2021. Mechanisms of Vertebrate DNA Interstrand Cross-Link Repair.. Annu Rev Biochem 90:107-135 PMID: 33882259
- 2. Tang J et al.. 2022. Preparation of DNA interstrand cross-link repair intermediates induced by abasic sites.. MethodsX 9:101687 PMID: 35492212
- 3. Silva P et al.. 2024. Germline Variants in DNA Interstrand-Cross Link Repair Genes May Contribute to Increased Susceptibility for Serrated Polyposis Syndrome.. Int J Mol Sci 25(21) PMID: 39519399
- 4. Hlavin EM et al.. 2010. Initiation of DNA interstrand cross-link repair in mammalian cells.. Environ Mol Mutagen 51(6):604-24 PMID: 20658650
- 5. Lehoczký P et al.. 2007. DNA interstrand cross-link repair in Saccharomyces cerevisiae.. FEMS Microbiol Rev 31(2):109-33 PMID: 17096663
- 6. Wang J et al.. 2024. Stable Interstrand Cross-Links Generated from the Repair of 1,N(6)-Ethenoadenine in DNA by α-Ketoglutarate/Fe(II)-Dependent Dioxygenase ALKBH2.. J Am Chem Soc 146(15):10381-10392 PMID: 38573229
- 7. Zhang J et al.. 2014. Mechanism and regulation of incisions during DNA interstrand cross-link repair.. DNA Repair (Amst) 19:135-42 PMID: 24768452
- 8. McHugh PJ et al.. 2006. DNA interstrand cross-link repair in the cell cycle: a critical role for polymerase zeta in G1 phase.. Cell Cycle 5(10):1044-7 PMID: 16687932
